致：香港交易及結算所有限公司 公司名稱: 長江生命科技集團有限公司 呈交日期: 2025年12月2日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00775 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 15,000,000,000 | | HKD | | 0.1 HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 15,000,000,000 | HKD | | 0.1 HKD | | 1,500,000,000 | 本月底法定/註冊股本 ...

Core Viewpoint - Changjiang Life Science Technology (00775) has seen a significant increase of over 8%, currently trading at 1.01 HKD, with a transaction volume of 23.28 million HKD, following the presentation of its cancer immunotherapy research results at the SITC 2025 conference [1] Group 1 - The company showcased major advancements in cancer vaccine development targeting TROP2, PRAME, and PD-L1, highlighting their potential to inhibit tumor growth [1] - Dr. Du Jianming, Vice President and Chief Scientific Officer of the company, expressed optimism about the results of the cancer vaccine candidates targeting TROP2 and PRAME/PD-L1, indicating that these developments could accelerate the progress of effective therapeutic cancer vaccines [1] - The current goal of the company is to advance these vaccine candidates to the clinical trial stage [1]

Core Viewpoint - Changjiang Life Science Technology (00775.HK) has seen a significant increase in its stock price, rising over 8% to HKD 1.01, with a trading volume of HKD 23.28 million [2] Group 1 - The stock price of Changjiang Life Science Technology increased by 8.6% [2] - The current trading price is reported at HKD 1.01 [2] - The total trading volume reached HKD 23.28 million [2]

Core Viewpoint - Changjiang Life Sciences (00775) saw a significant stock increase of 8.6%, reaching HKD 1.01, with a trading volume of HKD 23.28 million, following the presentation of its cancer immunotherapy research at the SITC 2025 conference [1] Group 1: Company Developments - Changjiang Life Sciences showcased its research advancements in cancer vaccines targeting TROP2, PRAME, and PD-L1 at the SITC 2025 conference [1] - The company’s Vice President and Chief Scientific Officer, Dr. Du Jianming, expressed optimism about the progress of the cancer vaccine candidates targeting TROP2 and PRAME/PD-L1, indicating a potential acceleration in the development of effective therapeutic cancer vaccines [1] - The current objective for the company is to advance these vaccine candidates to the clinical trial stage [1]

Core Viewpoint - Changjiang Life Science Technology (00775) has seen a significant stock increase of over 8%, currently trading at 1.01 HKD, with a transaction volume of 23.28 million HKD, following the presentation of its tumor growth inhibition research results at the SITC 2025 conference [1] Group 1: Company Developments - The company showcased major advancements in cancer vaccines targeting TROP2, PRAME, and PD-L1 at the SITC 2025 conference [1] - Dr. Du Jianming, Vice President and Chief Scientific Officer of the company, expressed optimism about the results of the cancer vaccine candidates targeting TROP2 and PRAME/PD-L1, indicating a potential acceleration in the development of effective therapeutic cancer vaccines [1] - The current goal for the company is to advance these vaccine candidates to the clinical trial stage [1]

Group 1 - The stock of Changjiang Life Science Technology (00775.HK) rose nearly 7% in the afternoon trading session, with a current increase of 6.82% [1] - The stock price is reported at 0.94 HKD, with a trading volume of 10.4298 million HKD [1]

Core Viewpoint - 长江生命科技 has demonstrated significant advancements in cancer immunotherapy, particularly in the development of innovative vaccines targeting specific cancer antigens, which has positively impacted its stock performance [1] Group 1: Stock Performance - Long江生命科技's stock rose nearly 7%, with a current increase of 6.82%, trading at 0.94 HKD, with a transaction volume of 10.43 million HKD [1] Group 2: Research and Development Achievements - The company showcased its research findings at the SITC 2025 conference, focusing on the development of cancer vaccines targeting TROP2, PRAME, and PD-L1, highlighting their potential to inhibit tumor growth [1] - Two innovative vaccines targeting TROP2 protein were disclosed, which is highly expressed in various cancers, including breast cancer, lung cancer, and colorectal cancer [1] - The company also announced the development of a vaccine that simultaneously targets PD-L1 and PRAME, with significant T-cell activation effects [1] - In a preventive lung cancer model, the vaccine demonstrated a tumor growth inhibition rate exceeding 95%, maintaining defensive capabilities even three months post-vaccination, indicating the potential for long-lasting immune memory [1]

Core Viewpoint - Changjiang Life Science (00775) experienced a nearly 7% increase in stock price, reaching 0.94 HKD, following the presentation of significant advancements in cancer immunotherapy at the SITC 2025 conference [1] Group 1: Company Developments - Changjiang Life Science showcased research results on tumor growth inhibition at the SITC 2025 conference, focusing on innovative cancer vaccines targeting TROP2, PRAME, and PD-L1 [1] - The company revealed two innovative vaccines targeting the TROP2 protein, which is highly expressed in various cancers including breast cancer, lung cancer, and colorectal cancer [1] - Additionally, the company announced the development of a vaccine that simultaneously targets PD-L1 and PRAME, with notable T-cell activation effects [1] Group 2: Research Outcomes - In a preventive lung cancer model, the vaccine demonstrated a tumor growth inhibition rate exceeding 95% after administration [1] - The vaccine maintained its defensive capability against tumor re-challenge tests three months post-vaccination, indicating the potential for inducing long-lasting immune memory [1]

Core Viewpoint - Changjiang Life Science Technology (00775) experienced a nearly 7% increase in stock price, attributed to the presentation of significant advancements in cancer immunotherapy at the SITC 2025 conference [1] Group 1: Company Developments - The company showcased research results on tumor growth inhibition, focusing on innovative cancer vaccines targeting TROP2, PRAME, and PD-L1 [1] - Two innovative vaccines targeting the TROP2 protein were disclosed, which is highly expressed in various cancers including breast, lung, and colorectal cancers [1] - The company also announced the development of a vaccine that simultaneously targets PD-L1 and PRAME, with notable T-cell activation effects [1] Group 2: Research Outcomes - In a preventive lung cancer model, the vaccine demonstrated a tumor growth inhibition rate exceeding 95% after administration [1] - The vaccine maintained its defensive capability against tumor re-challenge tests three months post-administration, indicating the potential for long-lasting immune memory [1]

致：香港交易及結算所有限公司 公司名稱: 長江生命科技集團有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00775 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 15,000,000,000 | HKD | | 0.1 HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 15,000,000,000 | HKD | | 0.1 HKD | | 1,500,000,000 | 本月底法定/註冊股本 ...